The short answer
The proposed ginkgo–nevirapine interaction has not been established in an exact-pair human study. Findings with other medicines do not reliably predict nevirapine levels or harm; review the actual supplement before use.
What this answer covers
Ginkgo biloba standardized leaf extracts; not seeds, injections or every retail product.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- nevirapine
What the original human studies show
A ginkgo study found unchanged total exposure to a CYP2B6 probe and its metabolite despite changes in some secondary measures. Another found lower midazolam exposure but unchanged boosted-protease-inhibitor exposure. These are not nevirapine studies.
Nevirapine has more than one metabolic pathway
Nevirapine is handled by CYP3A and CYP2B6 and induces its own metabolism over time. A CYP3A probe result alone cannot establish the overall change in nevirapine exposure, and a different antiretroviral is not an interchangeable test.
Preparation and outcome limits remain
The studies do not supply a nevirapine dose adjustment, clinical failure rate or safe supplement threshold. A laboratory marker, exposure result and clinical adverse event are different outcomes.
Review the full HIV regimen
Tell the HIV clinician which extract and dose you use. Do not interrupt or alter nevirapine to accommodate a supplement. Its serious liver and skin warnings remain important independently of any unproven herbal interaction.
Evidence and practical considerations
Absorption & effectiveness
No exact nevirapine combination result establishes the original claim. Human other-drug findings and nulls retained; CYP3A/CYP2B6, autoinduction and preparation differences prevent automatic exposure or toxicity transfer.
- Exact scope
- Ginkgo biloba standardized leaf extracts; not seeds, injections or every retail product. with Nevirapine immediate-release oral tablets; extended-release formulation considered separately.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed nevirapine
Serious hepatic and skin reactions; metabolism through CYP3A and CYP2B6 with autoinduction. St John’s wort co-use not recommended because of reduced exposure/virologic risk.
How this applies: Exact nevirapine RxCUI 53654 IN, with stated salt/formulation/route bridge.
Exact route and formulation apply. Label precautions do not quantify untested botanical pairs or support arbitrary supplement doses.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed nevirapine
Shares CYP3A/CYP2B6 metabolism, autoinduction and serious liver/skin precautions. Different release/dosing formulation.
How this applies: Exact nevirapine RxCUI 53654 IN, with stated salt/formulation/route bridge.
Immediate-release and extended-release schedules are not interchangeable without the prescribed transition plan.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Fourteen healthy young men.
No significant AUC change for bupropion or hydroxybupropion; metabolite peak and half-life changed.
How this applies: CYP2B6 probe study, not nevirapine; marker changes and total exposure are distinct.
CYP2B6 probe study, not nevirapine; marker changes and total exposure are distinct.
Source 4: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Fourteen healthy volunteers.
Midazolam exposure decreased; lopinavir, ritonavir and fexofenadine exposure not significantly changed.
How this applies: Boosted protease-inhibitor regimen and probe drugs, not nevirapine; single-sequence design.
Boosted protease-inhibitor regimen and probe drugs, not nevirapine; single-sequence design.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Editorial update | |
| Corrected missing spaces between numbers and units or words in the copy before registration; evidence and conclusions unchanged. | |
| Article prepared | |
| Prepared exact nevirapine article with formulation-specific evidence and uncertainty. |
Article revision: d5b0957b71ff17a5
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.